Search BlogCatalog

10 results of 17Blog Posts

Pfizer's R&D Productivity

In the Pipeline | December 10th 2009 by Derek Lowe

Courtesy of Bernard Munos, author of the Nature Reviews article that I began blogging about yesterday, comes this note about Pfizer's track record with new molecules. His list of Pfizer NMEs since 2000 is Geodon (ziprasidone, 2001), Vfend (voriconazo read more

Continuous Daily Sutent® Palliative in Patients with Relapsed or…

OncoBlog | November 5th 2009

Researchers from several U.S. and Spanish medical centers have reported that single-agent daily Sutent No related posts. [[ This is a content summary only. Visit my website for full links, other content, and more! ]] read more

Onyx Pharma and Proteolix look to tie the knot

Pharma Strategy Blog | October 12th 2009 by Sally Church

After the furore around Pfizer and figitumumab on Friday, this morning brought entirely different kind of news with Onyx Pharma seeking to purchase a small biotech based in South San Francisco called Proteolix.  Regular readers of this blog will be read more

Glaxo Kidney Cancer Drug Has Liver Risk, FDA Says

PharmaMics | October 2nd 2009 by Emad

GlaxoSmithKline Plc’s experimental treatment for advanced kidney cancer causes side effects, according to U.S. regulators weighing new competition to Pfizer Inc.’s Sutent.Glaxo’s pazopanib may be “associated with a significant risk” of seve read more

Sutent® Improves Progression-free Survival in Patients with Well…

OncoBlog | September 29th 2009

Researchers involved in an international randomized trial have reported that Sutent No related posts. [[ This is a content summary only. Visit my website for full links, other content, and more! ]] read more

Sutent for melanoma

Cancer Treatment Blog | September 25th 2009 by Josh

The FDA approved sunitinib in 2006 for patients with GIST. It has been shown that sunitinib malate works in these patients because of its activity against the KIT protein. The FDA also approved Sunitinib malate in 2006 for the treatment of metastatic read more

Everolimus (Afinitor®) Licensed in UK for Advanced Kidney Cancer…

Onco'Zine - The international Cancer Blog | September 24th 2009 by Peter Hofland, Phd

Everolimus (Afinitor®, Novartis AG, Basel, Switzerland) has recently been licensed in the United Kingdom for the treatment of advanced kidney cancer after failure of treatments which prevent the growth of the tumor’s blood vessels. The growth of t read more

What's hot at the ESMO conference this week?

Pharma Strategy Blog | September 24th 2009 by Sally Church

This week I'm snowed under with work, so was unable to attend the ECCO/ESMO conference, but have been following the key updates on Twitter and via press releases.  Here are a few snippets of data I found interesting and some analysis/commentary: read more

Sutent for kidney cancer approved on NHS but other drugs turned d…

PharmaMics | August 27th 2009 by Emad

read more

Health care smorgasbord

Thinking Objectively | August 19th 2009 by Henry Scuoteguazza

The indefatigable Robert Bidinotto constantly unearthes new articles on the health care debate and shares them on Facebook. I’ve provided some of them below with selected quotes. The first item is one I found, coming from Investor’s Business Dail read more

Top 5 Shown | View Next 5 results

View All Results

10 results of 10Social Search

Top 5 Shown | View Next 5 results

View All Results